MBIO - Mustang Bio Inc Stock Price, Fair Value and News

0.51USD-0.04 (-7.27%)Delayed

Market Summary

USD0.51-0.04

Delayed

-7.27%

MBIO Stock Price

View Fullscreen

MBIO RSI Chart

MBIO Valuation

Market Cap

4.1M

Price/Earnings (Trailing)

-0.08

Price/Sales (Trailing)

4.52

Price/Free Cashflow

-0.08

MBIO Price/Sales (Trailing)

MBIO Profitability

Return on Equity

-42.0K%

Return on Assets

-290.85%

Free Cashflow Yield

-1.2K%

MBIO Fundamentals

MBIO Revenue

Revenue (TTM)

917.0K

Rev. Growth (Yr)

-79.37%

Rev. Growth (Qtr)

-67.83%

MBIO Earnings

Earnings (TTM)

-51.6M

Earnings Growth (Yr)

56.12%

Earnings Growth (Qtr)

14.34%

Breaking Down MBIO Revenue

Last 7 days

-32.9%

Last 30 days

-47.4%

Last 90 days

-65.1%

Trailing 12 Months

-84.7%

How does MBIO drawdown profile look like?

MBIO Financial Health

Current Ratio

0.74

MBIO Investor Care

Shares Dilution (1Y)

3.58%

Diluted EPS (TTM)

-6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	1.7M	1.8M	917.0K
2022	367.0K	310.0K	894.0K	1.4M
2021	579.0K	522.0K	435.0K	0
2020	1.4M	1.1M	885.0K	708.0K
2019	575.0K	815.0K	1.1M	1.3M
2018	560.5K	573.5K	567.5K	569.0K
2017	138.1K	260.3K	382.4K	504.5K
2016	0	0	0	16.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Mustang Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 02, 2024	fortress biotech, inc.	acquired	-	-	419,092	-
Jul 05, 2023	zelefsky michael j	acquired	-	-	7,246	-
Jul 05, 2023	rosenwald lindsay a md	acquired	-	-	7,246	-
Jul 05, 2023	chill adam j.	acquired	-	-	7,246	-
Jul 05, 2023	herskowitz neil	acquired	-	-	7,246	-
Jul 05, 2023	weiss michael s	acquired	-	-	7,246	-
Apr 24, 2023	litchman manuel md	acquired	-	-	5,000	president and ceo
Jan 06, 2023	fortress biotech, inc.	acquired	-	-	2,807,010	-
Sep 13, 2022	rosenwald lindsay a md	bought	2,582	0.5164	5,000	-
Sep 13, 2022	litchman manuel md	bought	2,582	0.5164	5,000	-

Which funds bought or sold MBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	NBC SECURITIES, INC.	new	-	1,000	1,000	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.12	-125,176	242,408	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-9,000	-	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-10.65	-1,000	-	-%
Feb 14, 2024	MACQUARIE GROUP LTD	unchanged	-	-5,000	11,000	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	30.66	-9,334	57,537	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-153	285	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-39.00	76.00	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-11,212	21,623	-%

Are Funds Buying or Selling MBIO?

Are funds buying MBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MBIO

No. of Funds

Unveiling Mustang Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	974,907	SC 13G
Jan 13, 2023	fortress biotech, inc.	20.7%	22,880,620	SC 13D/A
Jul 08, 2022	blackrock inc.	2.2%	2,263,156	SC 13G
Feb 04, 2022	blackrock inc.	6.2%	5,754,566	SC 13G
Apr 12, 2021	blackrock inc.	4.7%	3,984,922	SC 13G/A
Feb 02, 2021	blackrock inc.	5.2%	3,344,681	SC 13G

Recent SEC filings of Mustang Bio Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	8-K	Current Report
Apr 02, 2024	S-1/A	Initial Public Offering
Mar 29, 2024	8-K	Current Report
Mar 15, 2024	S-1	Initial Public Offering
Mar 15, 2024	8-K	Current Report
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	8-K	Current Report
Feb 12, 2024	3	Insider Trading

Peers (Alternatives to Mustang Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.2B	6.8B	-1.24%	-34.47%	-8.53	5.87	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.7B	1.8B	0.05%	-28.38%	-42.48	10.23	76.23%	61.08%
BMRN	17.4B	2.4B	8.82%	-6.19%	103.82	7.19	15.42%	18.43%
INCY	12.1B	3.7B	-8.57%	-28.49%	20.24	3.27	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.73%	-34.59%	-11.81	15.74	425.83%	18.94%
BBIO	4.7B	-	-4.69%	71.46%	-7.23	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-0.99%	6.40%	-13.71	12.12	440.80%	-27.84%
ARWR	3.1B	240.7M	-13.54%	-18.95%	-10.32	12.72	-1.03%	-92.09%
ACAD	2.8B	726.4M	-12.42%	-7.51%	-46.06	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-15.36%	25.1	4.5	85.90%	-14.05%
NVAX	599.0M	983.7M	-18.48%	-55.04%	-1.1	0.61	-50.36%	17.16%
CRBP	428.3M	881.7K	-13.30%	407.71%	-9.6	466.16	-77.61%	-5.33%
INO	257.8M	4.9M	-1.96%	-2.22%	-1.91	52.97	-54.97%	51.72%
IBIO	7.2M	2.1M	77.59%	88.99%	-0.26	2.14	-13.45%	66.37%

Mustang Bio Inc News

Latest updates

Mustang Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-100.0%	-	138	429	560	669	77.00	73.00	75.00	85.00	134	141	162	142	263	318	406	387	152	138	138	147
Operating Expenses	-15.2%	8,741	10,307	13,891	19,432	18,848	18,241	19,638	17,077	14,440	15,087	20,738	10,427	14,121	11,520	15,923	9,996	10,212	9,754	11,875	7,656	5,240
S&GA Expenses	2.3%	2,179	2,131	3,055	2,395	3,389	3,077	3,349	2,364	2,538	3,469	2,405	2,153	2,991	1,956	2,050	1,987	3,189	2,344	1,651	1,340	1,683
Interest Expenses	-175.0%	-3.00	4.00	2,932	1,160	1,034	935	230	3.00	4.00	4.00	-2,313	2,687	619	600	604	578	574	11.00	8.00	-	-
Net Income	14.3%	-8,616	-10,058	-16,235	-19,634	-18,997	-19,099	-19,795	-17,005	-14,359	-14,957	-20,608	-12,952	-14,598	-11,857	-16,209	-10,168	-10,399	-9,613	-11,770	-7,518	-5,093
Net Income Margin	-61.4%	-56.27*	-34.87*	-41.24*	-56.22*	-87.18*	-244.99*	-194.03*	-153.86*	-120.45*	-109.01*	-84.77*	-62.84*	-46.80*	-35.40*	-36.73*	-38.73*	-48.22*	-59.12*	-53.89*	-60.78*	-59.14*
Free Cashflow	39.4%	-7,284	-12,023	-12,426	-15,384	-16,892	-17,881	-17,623	-11,749	-13,786	-16,038	-10,172	-10,262	-8,132	-10,678	-10,381	-9,329	-9,434	-6,782	-6,827	-4,948	-8,098

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-13.7%	18.00	21.00	29.00	74.00	92.00	109	122	137	125	135	143	142	110	86.00	97.00	69.00	73.00	84.00	93.00	50.00	43.00
Current Assets	-16.5%	11.00	14.00	23.00	61.00	79.00	94.00	109	124	112	122	131	131	100	76.00	86.00	58.00	63.00	74.00	83.00	42.00	35.00
Cash Equivalents	-27.0%	7.00	10.00	15.00	58.00	76.00	91.00	107	122	111	121	130	129	99.00	75.00	85.00	57.00	62.00	73.00	83.00	36.00	17.00
Liabilities	6.4%	18.00	17.00	15.00	44.00	46.00	45.00	40.00	40.00	13.00	12.00	8.00	8.00	11.00	10.00	26.00	23.00	22.00	21.00	21.00	22.00	6.00
Current Liabilities	8.5%	15.00	14.00	13.00	13.00	15.00	14.00	11.00	11.00	11.00	10.00	6.00	7.00	10.00	8.00	15.00	10.00	8.00	6.00	6.00	7.00	6.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.00	3.00	1.00	-	-	-	-
Shareholder's Equity	-96.9%	0.00	4.00	14.00	30.00	46.00	64.00	82.00	97.00	112	122	135	133	98.00	76.00	71.00	46.00	52.00	62.00	71.00	28.00	36.00
Retained Earnings	-2.3%	-380	-372	-362	-346	-329	-309	-290	-271	-251	-231	-214	-200	-185	-164	-151	-137	-125	-109	-99.08	-88.68	-79.07
Additional Paid-In Capital	1.1%	381	376	376	376	375	374	373	369	360	354	350	334	276	241	223	183	172	172	171	117	113
Shares Outstanding	-100.0%	-	8.00	8.00	8.00	7.00	8.00	7.00	7.00	6.00	6.00	6.00	5.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00
Float	-	-	-	-	-	-	-	49.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	39.7%	-7,254	-12,023	-12,392	-17,808	-15,289	-15,913	-17,575	-16,289	-14,703	-11,289	-12,095	-15,580	-9,475	-10,124	-7,568	-10,152	-9,490	-8,830	-8,778	-6,483	-6,523
Share Based Compensation	88.0%	188	100	45.00	235	473	496	650	664	881	884	547	996	619	606	957	805	490	1,120	622	432	1,091
Cashflow From Investing	-100.5%	-30.00	5,950	-34.00	-	-420	-892	-306	-1,334	-1,477	-990	-2,441	-458	-1,464	-1,608	-814	-526	-1,391	-899	4,198	12,001	4,696
Cashflow From Financing	1482.4%	3,956	250	-30,287	-	1.00	800	3,034	30,221	4,919	3,235	15,088	47,605	33,492	1,622	37,929	5,079	-	-111	51,614	13,613	-

MBIO Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 40,513	$ 62,475
Research and development - licenses acquired	527	1,474
Gain on the sale of property and equipment	(1,466)
General and administrative	9,686	12,210
Total operating expenses	49,260	76,159
Loss from operations	(49,260)	(76,159)
Other income (expense)
Other income	917	1,304
Interest income	850	689
Interest expense	(4,109)	(3,359)
Total other income (expense)	(2,342)	(1,366)
Net Loss	$ (51,602)	$ (77,525)
Net loss per common share outstanding, basic	$ (6.00)	$ (10.09)
Net loss per common share outstanding, diluted	$ (6.00)	$ (10.09)
Weighted average number of common shares outstanding, basic	8,604,104	7,684,508
Weighted average number of common shares outstanding, diluted	8,604,104	7,684,508

MBIO Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 6,234,000	$ 75,656,000
Prepaid expenses and other current assets	1,233,000	2,897,000
Total current assets	11,346,000	78,852,000
Property, plant and equipment, net	3,218,000	8,440,000
Fixed assets - construction in process	29,000	951,000
Restricted cash	750,000	1,000,000
Other assets	833,000	261,000
Operating lease right-of-use asset, net	1,566,000	2,918,000
Total Assets	17,742,000	92,422,000
Current Liabilities:
Accounts payable and accrued expenses	14,017,000	13,731,000
Operating lease liabilities - short-term	520,000	612,000
Total current liabilities	15,371,000	15,109,000
Deferred income	270,000	270,000
Note payable, long-term, net	0	27,436,000
Operating lease liabilities - long-term	1,978,000	3,334,000
Total Liabilities	17,619,000	46,149,000
Commitments and Contingencies (Note 7)
Stockholders' Equity
Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	0	0
Common stock issuable, 419,089 and 187,134 shares as of December 31, 2023 and December 31, 2022, respectively	591,000	1,109,000
Additional paid-in capital	380,502,000	374,522,000
Accumulated deficit	(380,971,000)	(329,369,000)
Total Stockholders' Equity	123,000	46,273,000
Total Liabilities and Stockholders' Equity	17,742,000	92,422,000
Related Party [Member]
Current Assets:
Other receivables	0	36,000
Current Liabilities:
Payables and accrued expenses - related party	834,000	766,000
Nonrelated Party [Member]
Current Assets:
Other receivables	3,879,000	263,000
Class A common shares
Stockholders' Equity
Common stock ($0.0001 par value), 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively	0	0
Common shares
Stockholders' Equity
Common stock ($0.0001 par value), 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively	$ 1,000	$ 11,000

About Mustang Bio Inc

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

CEO	Dr. Manuel Litchman M.D.
WEBSITE	mustangbio.com
INDUSTRY	Biotechnology
EMPLOYEES	113

Mustang Bio Inc Frequently Asked Questions

What is the ticker symbol for Mustang Bio Inc? What does MBIO stand for in stocks?

MBIO is the stock ticker symbol of Mustang Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mustang Bio Inc (MBIO)?

As of Fri Apr 12 2024, market cap of Mustang Bio Inc is 4.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MBIO stock?

You can check MBIO's fair value in chart for subscribers.

What is the fair value of MBIO stock?

You can check MBIO's fair value in chart for subscribers. The fair value of Mustang Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mustang Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mustang Bio Inc a good stock to buy?

The fair value guage provides a quick view whether MBIO is over valued or under valued. Whether Mustang Bio Inc is cheap or expensive depends on the assumptions which impact Mustang Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBIO.

What is Mustang Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, MBIO's PE ratio (Price to Earnings) is -0.08 and Price to Sales (PS) ratio is 4.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MBIO PE ratio will change depending on the future growth rate expectations of investors.